LGND up +3.50% percent Today $LGND High is at 57.76 and the

New Post Public Reply Private Reply Replies (0) Message Board

Nov 11, 2014 at 12:42 PM

LGND up +3.50% percent Today $LGND High is at 57.76 and the Low 55.60 with current volume of 160,705.

Recent News posted below.

Ligand Pharmaceuticals Inc LGND other info.
http://investorshangout.com/Ligand-Pharmaceut...GND-54621/

LGND Ligand Pharmaceuticals Inc Recent Headline News

Shares of LGND Up 13.9% Since Uptrend Call on Shares
Comtex SmarTrend(R) - 2 hrs 18 mins ago
SmarTrend identified an Uptrend for Ligand Pharmaceuticals (NASDAQ:LGND) on October 17th, 2014 at $48.85. In approximately 4 weeks, Ligand Pharmaceuticals has returned 13.91% as of today's recent price of $55.64.
LGND: 58.26 (+2.58)

Merck presents data from its investigational HCV combo
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 8:37AM CST

JNJ: 108.99 (+0.17), GILD: 108.41 (+1.39), ACHN: 13.04 (+0.19), CNAT: 7.06 (unch), MRK: 59.57 (+0.76), LGND: 58.26 (+2.58), RGLS: 20.41 (-0.50), ABBV: 63.99 (+0.20), BMY: 58.97 (+0.16), ENTA: 43.41 (-0.73)

Gilead presents data from three HCV drug combo studies
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 8:05AM CST

JNJ: 108.99 (+0.17), GILD: 108.41 (+1.39), ACHN: 13.04 (+0.19), CNAT: 7.06 (unch), LGND: 58.26 (+2.58), RGLS: 20.41 (-0.50), ABBV: 63.99 (+0.20), BMY: 58.97 (+0.16), ENTA: 43.51 (-0.63)

Post Earnings Update: Ligand Pharmaceuticals Has Sunk 0.5% Lower in Past 2 Weeks (LGND)
Comtex SmarTrend(R) - Mon Nov 10, 11:52AM CST
When Ligand Pharmaceuticals (NASDAQ:LGND) reported earnings 14 days ago on October 27th, 2014, analysts, on average, expected the company to report earnings of $0.33 on sales of $14.9 million. The company actually reported EPS of $0.06 on sales of $15.0 million, missing EPS estimates by $0.27 and matching revenue estimates. Shares of Ligand Pharmaceuticals have slipped from $54.23 to $53.94, representing a loss of 0.5%, since the company reported earnings 14 days ago.
LGND: 58.26 (+2.58)

Merck triple therapy HCV candidate fails as a four-week regimen
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 6:49AM CST

JNJ: 108.99 (+0.17), GILD: 108.41 (+1.39), CNAT: 7.06 (unch), MRK: 59.58 (+0.77), LGND: 58.26 (+2.58), RGLS: 20.41 (-0.50), ABBV: 63.99 (+0.20), BMY: 58.97 (+0.16), ENTA: 43.51 (-0.63)

Bristol-Myers presents data on HCV Trio regimen
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 5:04PM CST

JNJ: 108.99 (+0.17), GILD: 108.41 (+1.39), CNAT: 7.06 (unch), MRK: 59.58 (+0.77), LGND: 58.26 (+2.58), RGLS: 20.41 (-0.50), ABBV: 63.99 (+0.20), BMY: 58.97 (+0.16), ENTA: 43.51 (-0.63)

Bristol-Myers presents data on shorter regimen HCV drug combo
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:37PM CST

JNJ: 108.99 (+0.17), GILD: 108.41 (+1.39), CNAT: 7.06 (unch), MRK: 59.58 (+0.77), LGND: 58.26 (+2.58), RGLS: 20.41 (-0.50), ABBV: 63.99 (+0.20), BMY: 58.97 (+0.16), ENTA: 43.51 (-0.63)

Achillion presents HCV data at The Liver Meeting
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:06PM CST

JNJ: 108.99 (+0.17), GILD: 108.41 (+1.39), ACHN: 13.04 (+0.19), CNAT: 7.06 (unch), MRK: 59.58 (+0.77), LGND: 58.26 (+2.58), RGLS: 20.41 (-0.50), ABBV: 63.99 (+0.20), BMY: 58.97 (+0.16), ENTA: 43.51 (-0.63)

Ligand Pharmaceuticals Shares Up 12.9% Since SmarTrend's Buy Recommendation (LGND)
Comtex SmarTrend(R) - Mon Nov 03, 10:02AM CST
SmarTrend identified an Uptrend for Ligand Pharmaceuticals (NASDAQ:LGND) on October 17th, 2014 at $48.85. In approximately 2 weeks, Ligand Pharmaceuticals has returned 12.89% as of today's recent price of $55.14.
LGND: 58.26 (+2.58)

Ligand Pharmaceuticals' Shares Fall on Q3 Earnings Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 1:00PM CDT
Ligand Pharmaceuticals Incorporated (LGND) reported higher third-quarter earnings of 19 cents per share but fell short of the Zacks Consensus Estimate by 2 cents.
BIIB: 326.81 (-1.06), LGND: 58.26 (+2.58), AMGN: 163.25 (+0.16), GSK: 45.80 (+0.64)

Ligand Pharmaceuticals Has Rich A Valuation Now But Is Undervalued For Long Term Success
Chris Katje - at Seeking Alpha - Wed Oct 29, 10:34AM CDT

PFE: 30.20 (unch), AZN: 74.23 (+1.02), LGND: 58.26 (+2.58), AMGN: 163.25 (+0.16), GSK: 45.80 (+0.64)

Update: Ligand Posts Consecutive Earnings Beat
Trevor Lowenthal - at Seeking Alpha - Tue Oct 28, 3:21PM CDT

LGND: 58.26 (+2.58)

Ligand Pharmaceuticals' (LGND) CEO Steve Holmes on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Oct 27, 1:56PM CDT

LGND: 58.26 (+2.58)

Ligand Pharmaceuticals reaffirms full year 2014 guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 8:31AM CDT

LGND: 58.26 (+2.58)

Ligand beats Street 3Q forecasts
Automated Insights - Mon Oct 27, 7:16AM CDT
LA JOLLA, Calif. (AP) _ Ligand Pharmaceuticals Inc. (LGND) on Monday reported third-quarter net income of $1.3 million.
LGND: 58.26 (+2.58)

Ligand Pharmaceuticals beats by $0.05, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 7:07AM CDT

LGND: 58.26 (+2.58)

Ligand Reports Third Quarter 2014 Financial Results
Business Wire - Mon Oct 27, 7:01AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and nine months ended September 30, 2014, and provided an operating forecast and program updates.
LGND: 58.26 (+2.58)

Notable earnings before Monday’s open
Seeking Alpha - at Seeking Alpha - Sun Oct 26, 4:30PM CDT

ROP: 157.40 (-1.13), SIR: 24.19 (-0.05), VNDA: 12.83 (+0.67), STX: 61.65 (-0.12), NMM: 13.64 (unch), LGND: 58.26 (+2.58), PDS: 7.82 (+0.06), TREX: 44.00 (-0.01), EXAS: 22.59 (-0.01), AWI: 49.17 (unch), EDR: 11.58 (-0.04), HUN: 24.96 (+0.03), TEN: 53.19 (-0.25), AGN: 195.84 (+0.60), ONB: 14.85 (-0.06), STNG: 8.75 (+0.11), MRK: 59.58 (+0.77), BEN: 56.75 (+0.18)

Will Pfizer (PFE) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 24, 4:20PM CDT
Pfizer (PFE) is scheduled to report third-quarter 2014 results before the opening bell on Oct 28.
VRTX: 117.54 (+0.60), PFE: 30.20 (unch), LGND: 58.26 (+2.58), TEVA: 58.55 (+0.51)

Will Merck (MRK) Pull a Surprise this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 24, 4:10PM CDT
Merck & Co. Inc. (MRK) is scheduled to report third-quarter 2014 results before the opening bell on Oct 27.
MRK: 59.58 (+0.77), LGND: 58.26 (+2.58), TEVA: 58.55 (+0.51)

Ligand Pharmaceuticals Inc. (LGND) Stock Research Links

LGND Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Celebree School Champions Screen-Free Imagination Era

Nostalgia often carries us back to simpler times, whether it's building blanket forts or putting on living room plays. Today, these memories are stirring up a movement, and Celebree School is at the heart of the whirlwind. They're rolling out a campaign aptly titled "Boredom Is Where Imagination Begins," aimed at reintroducing children to creativity beyond screens and...

ZonPrep Expands With Key Software Acquisitions

The Brains Behind the Boxes ZonPrep just hammered a significant nail into the logistics game with their latest acquisitions. They've snapped up Wizard-Industries and FNSKU Studio. Why should you care? Well, these platforms are the secret sauce behind efficient inventory management into Amazon's wild-west of warehouses. While not every Tom, Dick, or Harry can navigate that...

Highlandia's THC Elixirs Land Big Wins, Expand Reach

Highlandia Takes Center Stage at 2026 PR%F Awards Out of the gate, Highlandia not just walked but sprinted its way to the forefront of the THC beverage sector. This little brand out of Kenosha snagged the spotlight at the 2026 Summer PR%F Awards with its Rocket Peak flavor bagging the Best in Show award. Now, that's a headline any marketer would kill for. It's a triumph...

BKF's Strategic Move: Andrew Esposito Steps In Don't walk past a headline like this without feeling the pulse of BKF's ambitious strides in the AEC industry. BKF, a heavyweight in the architecture, engineering, and construction sector, has tapped Andrew Esposito as its new Chief Financial Officer. Based out in sunny Oakland, California, they're looking to crank up their...

HiTHIUM Surges in Global Energy Storage Battle

Man, those aren't small potatoes in the energy storage realm! HiTHIUM’s blitz on the global rankings has caught my eye, and I don’t toss around praise lightly. The news out of Xiamen is that HiTHIUM secured the number two spot globally in energy storage battery shipments once again. That’s not just a medal; it’s a flashing beacon in a sector skyrocketing faster...

SCO at 25: China's Strategic Push for Regional Growth

There's a new beat coming out of Central Asia, and it's resonating all the way from China's boardrooms to the barren landscapes of the Gobi Desert. With the Shanghai Cooperation Organization (SCO) celebrating its 25th anniversary, we're witnessing a pivot from a security-centric setup to a full-blown economic collaboration machine. The Landscape of SCO's Evolution Look,...

Francois de Visscher: An Advisor's Legacy and Future

A Long Journey in Advisory and Diplomacy Francois M. de Visscher might not be a household name at your typical Wall Street gathering, yet his contributions have quietly influenced how family businesses are managed across the globe. Here’s a guy who hasn't just played the game; he’s designed some of the rules. With roots tracing back to Belgium and academic credentials...

Cogent Communications Faces Investor Legal Battle

Bumps on the Cogent Communications Road Things always look clear in hindsight, and for Cogent Communications Holdings (NASDAQ: CCOI), that rearview might be filled with red flags they've ignored too long. Here we are, a securities fraud class action hanging over their heads because they couldn't keep clean financial house. The Numbers Don't Lie Cogent's Q2 2026 numbers...

Sister Accord Foundation's Big Weekend of Impact & Harmony

A Weekend Celebrating Sisterhood and Progress In Cincinnati, a community burst into celebration not just for a day, but an entire weekend, marking the 13th anniversary of Sister Accord Day. This event felt bigger than the usual fanfare—there was talk of leadership, scholarships, and music, all woven together with a commitment to change how women support each other. It...

Tiger Group Offloads High-End Equipment in Swift Sale

Fast Moves in Manufacturing Equipment Liquidation Alright, gather 'round. Tiger Commercial & Industrial (C&I) recently wrapped up a speedy sale of high-precision fabrication and assembly machinery from two U.S. plants. We're talking about substantial inventory here, including equipment from once-bustling facilities in Alpharetta, Georgia, and Dallas, Texas. This wasn't...